Rockefeller Capital Management
EPIX

Rockefeller Capital Management’s ESSA Pharma EPIX Stock Holding History

Rockefeller Capital Management’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-132
Closed – – 4001
2022
Q2 		$0 Buy
+132
New +$737 ﹤0.01% 4176

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Rockefeller Capital Management's EPIX Position: Q3 2022 in Review

Rockefeller Capital Management sold out of ESSA Pharma (EPIX) in Q3 2022, closing a stake of 132 shares.

Rockefeller Capital Management first reported a position in EPIX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 54 funds tracked by Wall St. Rank hold EPIX as of Q3 2022.

  • Rockefeller Capital Management reported no remaining ESSA Pharma position as of Q3 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 132 ESSA Pharma shares in Q3 2022.
  • Rockefeller Capital Management first reported a position in ESSA Pharma in Q2 2022 and held it in 1 quarter.
  • Rockefeller Capital Management's ESSA Pharma position peaked at $0 in Q2 2022.
  • 54 funds tracked by Wall St. Rank held ESSA Pharma as of Q3 2022.

Based on Rockefeller Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.